39,073 results match your criteria Lymphoma Diffuse Large Cell

Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma.

Transplant Cell Ther 2022 Jun 22. Epub 2022 Jun 22.

Division of Hematology, Mayo Clinic, Rochester, MN, USA. Electronic address:

Background: Patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who achieve progression-free survival (PFS) at 24 months (PFS24) following immunochemotherapy (IC) have excellent overall survival (OS) comparable to that of the age- and sex-matched general population. However, a similar landmark has not been established for patients with relapsed or refractory (RR) DLBCL following frontline IC who are subsequently treated with salvage therapy followed by autologous stem cell transplant (ASCT).

Objective: To evaluate the role of PFS24 as a landmark after ASCT in patients with RR DLBCL. Read More

View Article and Full-Text PDF

Primary Breast Lymphoma Mimicking Metastatic Breast Cancer on 18F-FDG PET-CT.

J Pak Med Assoc 2022 Jun;72(6):1241-1242

Department of Hematology, Kuwait Cancer Control Center, Kuwait.

18F-Fluorodeoxyglucose (FDG) PET-CT is an excellent imaging modality for the evaluation of non-Hodgkin lymphoma (NHL). We report a case of a 45-year-old woman presented with a large right breast mass and suspicious right axillary lymph nodes referred for 18F-FDG PET-CT for staging. 18F-FDG PET-CT images show large hypermetabolic right breast mass infiltrating the skin, multiple hypermetabolic right axillary and subpectoral lymph nodes, along with multiple hypermetabolic bone lesions at axial and appendicular skeleton. Read More

View Article and Full-Text PDF

Ocular recurrence of primary central nervous system diffuse large B-cell lymphoma: A case report.

Asian J Surg 2022 Jun 21. Epub 2022 Jun 21.

Department of Pathology, The First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, No. 155 Nanjing North Street, Heping District, Shenyang, Liaoning, 110001, PR China. Electronic address:

View Article and Full-Text PDF

Pathway importance by graph convolutional network and Shapley additive explanations in gene expression phenotype of diffuse large B-cell lymphoma.

PLoS One 2022 24;17(6):e0269570. Epub 2022 Jun 24.

Department of Biomedical Informatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Deep learning techniques have recently been applied to analyze associations between gene expression data and disease phenotypes. However, there are concerns regarding the black box problem: it is difficult to interpret why the prediction results are obtained using deep learning models from model parameters. New methods have been proposed for interpreting deep learning model predictions but have not been applied to genetics. Read More

View Article and Full-Text PDF

Development and Characterization of 3D Hybrid Spheroids for the Investigation of the Crosstalk Between B-Cell Non-Hodgkin Lymphomas and Mesenchymal Stromal Cells.

Onco Targets Ther 2022 17;15:683-697. Epub 2022 Jun 17.

Flow Cytometry Laboratory, Department of Cancer Pathomorphology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.

Purpose: B-cell non-Hodgkin lymphomas (B-NHLs) are the most common lymphoproliferative malignancy. Despite targeted therapies, the bone marrow involvement remains a challenge in treating aggressive B-NHLs, partly due to the protective interactions of lymphoma cells with mesenchymal stromal cells (MSCs). However, data elucidating the relationship between MSCs and B-NHLs are limited and inconclusive due to the lack of reproducible in vitro three-dimensional (3D) models. Read More

View Article and Full-Text PDF

Hormonal Changes after R-CHOP Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma: A Prospective Study.

Medicina (Kaunas) 2022 May 26;58(6). Epub 2022 May 26.

Clinical Epidemiology and Clinical Statistic Center, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.

: There is a lack of data regarding hormonal metabolic abnormalities resulting from the R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone), a commonly used chemotherapy in diffuse large B-cell lymphoma (DLBCL). This study aimed to determine the incidence of hormonal and metabolic changes after R-CHOP therapy. : This prospective cohort study initially included 17 DLBCL patients. Read More

View Article and Full-Text PDF

Systems Drug Discovery for Diffuse Large B Cell Lymphoma Based on Pathogenic Molecular Mechanism via Big Data Mining and Deep Learning Method.

Int J Mol Sci 2022 Jun 16;23(12). Epub 2022 Jun 16.

Laboratory of Automatic Control, Signal Processing and Systems Biology, Department of Electrical Engineering, National Tsing Hua University, Hsinchu 30013, Taiwan.

Diffuse large B cell lymphoma (DLBCL) is an aggressive heterogeneous disease. The most common subtypes of DLBCL include germinal center b-cell (GCB) type and activated b-cell (ABC) type. To learn more about the pathogenesis of two DLBCL subtypes (i. Read More

View Article and Full-Text PDF

Metabolic Biomarkers Assessed with PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients with Diffuse Large B-Cell Lymphoma.

Cancers (Basel) 2022 Jun 14;14(12). Epub 2022 Jun 14.

Department of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA.

In many cancers, including lymphoma, males have higher incidence and mortality than females. Emerging evidence demonstrates that one mechanism underlying this phenomenon is sex differences in metabolism, both with respect to tumor nutrient consumption and systemic alterations in metabolism, i.e. Read More

View Article and Full-Text PDF

Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective.

Cancers (Basel) 2022 Jun 13;14(12). Epub 2022 Jun 13.

Department of Pediatrics, CARTOX Program, Pediatric Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Non-Hodgkin lymphoma (NHL) is a broad entity which comprises a number of different types of lymphomatous malignancies. In the pediatric and adolescent population, the type and prognosis of NHL varies by age and gender. In comparison to adults, pediatric and adolescent patients generally have better outcomes following treatment for primary NHL. Read More

View Article and Full-Text PDF

Presence of a mouse mammary tumour virus-like in feline lymphomas: a preliminary study.

Infect Agent Cancer 2022 Jun 23;17(1):35. Epub 2022 Jun 23.

Dipartimento di Scienze Veterinarie, Università di Pisa, Viale delle Piagge, 2, 56124, Pisa, Italy.

The mouse mammary tumour virus (MMTV) is implicated in the aetiology of murine mammary carcinomas and a variant of it, the type B leukemogenic virus, can cause murine thymic lymphomas. Interestingly, a MMTV-like virus is suspected to be involved in human breast cancer and feline mammary carcinomas. However, to date, no cases of MMTV-like sequence amplifications have been described in lymphoid neoplasms in veterinary literature. Read More

View Article and Full-Text PDF

C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Patients with Advanced T-Cell Lymphoma.

J Nucl Med 2022 Jun 23. Epub 2022 Jun 23.

Department of Nuclear Medicine, University Hospital Würzburg, Germany.

C-X-C motif chemokine receptor 4 (CXCR4)-targeted radioligand therapy (RLT) has already been applied to advanced blood cancers, such as multiple myeloma or diffuse large B-cell lymphoma. We herein present a series of patients with advanced T-cell lymphoma (TCL), who were scheduled for CXCR4-directed therapy as conditioning regimen, followed by hematopoietic stem cell transplantation (HSCT). Four patients with advanced, heavily pretreated and relapsed TCL (2 males, 2 females; median age, 50 years) without suitable alternative therapeutic options underwent CXCR4-directed PET and pretherapeutic dosimetry. Read More

View Article and Full-Text PDF

Outcomes of elderly diffuse large B-cell lymphoma patients treated with R-CHOP: 10-year follow-up of the LNH03-6B trial.

Blood Adv 2022 Jun 23. Epub 2022 Jun 23.

INSERM U1245, Centre Henri Becquerel, University of Rouen, France.

The LNH03-6B trial was a phase 3 randomized trial evaluating the efficacy of first-Line R-CHOP delivered every 2 weeks (R-CHOP14) or 3 weeks (R-CHOP21) in diffuse large B-cell lymphoma patients aged 60-80 years with an age-adjusted IPI score greater than or equal to 1 (registered as NCT00144755). We implemented a prospective long-term follow-up (LTFU) program at the end of this trial. The primary endpoints were progression-free survival (PFS) and Overall survival (OS). Read More

View Article and Full-Text PDF

Diffuse Large B-Cell Lymphoma with Axillary Cutaneous Invasion in a HIV Positive Patient.

Acta Med Port 2022 Jun 22. Epub 2022 Jun 22.

Serviço de Doenças Infecciosas. Hospital de Curry Cabral. Centro Hospitalar Universitário de Lisboa Central, EPE. Lisboa. Portugal.

View Article and Full-Text PDF

Plasma Metabolites Forecast Occurrence and Prognosis for Patients With Diffuse Large B-Cell Lymphoma.

Front Oncol 2022 6;12:894891. Epub 2022 Jun 6.

Phase I Clinical Trials Unit, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.

Background: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma with considerable heterogeneity and different clinical prognosis. However, plasma metabomics used to forecast occurrence and prognosis of DLBCL are rarely addressed.

Method: A total of 65 volunteers including 22 healthy controls (Ctrl), 25 DLBCL patients newly diagnosed (ND), and 18 DLBCL patients achieving complete remission (CR) were enrolled. Read More

View Article and Full-Text PDF

Case Report: Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights.

Front Oncol 2022 6;12:917115. Epub 2022 Jun 6.

Division of Hematology, University of Torino, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy.

Two main variants of Richter syndrome (RS) are recognized, namely, the diffuse large B-cell lymphoma (DLBCL) and the Hodgkin's lymphoma (HL) variant. Clonal relationship, defined as an identity of the immunoglobulin heavy chain variable (IGHV) region sequence between chronic lymphocytic leukemia (CLL) and RS clones, characterizes patients with a poor prognosis. Due to method sensitivity, this categorization is performed without considering the possibility of small-size ancillary clones, sharing the same phenotype with the preexisting predominant CLL clone, but with different IGHV rearrangements. Read More

View Article and Full-Text PDF

Clinical Features, Diagnosis, and Treatment of Primary Intraventricular Lymphoma: Insights From a Monocentric Case Series.

Front Neurol 2022 6;13:920505. Epub 2022 Jun 6.

Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Objective: Primary ventricular lymphoma (PVL) is an extremely rare and commonly misdiagnosed disease. Previous studies were predominantly case reports, and literature regarding the diagnosis and treatment of PVL is limited. Therefore, this study aimed to evaluate the characteristics of patients with PVL. Read More

View Article and Full-Text PDF

Two cases of EBV infection preceding lymphoma.

J Cancer Res Clin Oncol 2022 Jun 22. Epub 2022 Jun 22.

Medical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Medical Center Bonn (UKB), Venusberg-Campus 1, 53127, Bonn, Germany.

Infection of lymphocytes with the Epstein-Barr virus (EBV) is a well-documented risk factor for developing lymphoma. The incidence of EBV positivity in lymphoma depends on the subtype and can range from 10% in diffuse large B-cell lymphoma (DLBCL) to 100% in endemic Burkitt lymphoma (BL), (Shannon-Lowe and Rickinson, Front Oncol 9:713, 2019). However, in most cases, EBV infection remains unnoticed until diagnosis of lymphoma is made. Read More

View Article and Full-Text PDF

High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up.

Sci Rep 2022 Jun 22;12(1):10551. Epub 2022 Jun 22.

Department of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology, 5 WK Roentgen Str, 02-781, Warsaw, Poland.

Primary mediastinal B-cell lymphoma (PMBL) is currently curable in 85-95% of patients. Treatment regimens frequently used include RCHOP ± radiotherapy, DAEPOCH-R, or occasionally more intensive protocols. Here we present results of treatment of 124 patients with PMBL over a period between 2004 and 2017 with the use of a protocol designed for aggressive B-cell lymphoma GMALL/B-ALL/NHL2002 including 6 cycles of alternating immunochemotherapy with intermediate-dose methotrexate in each cycle, and reduced total doxorubicin dose (100 mg/m for whole treatment). Read More

View Article and Full-Text PDF

Ovarian Follicular Lymphoma Diagnosed due to Hydronephrosis.

Intern Med 2022 Jun 21. Epub 2022 Jun 21.

Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Japan.

A 74-year-old woman presented with left lateral abdominal pain. Abdominal echography revealed left hydronephrosis and a pelvic mass. The patient underwent left adnexal resection of a suspected left ovarian tumor and was diagnosed with follicular lymphoma (FL) of clinical stage IIIA, grade 2. Read More

View Article and Full-Text PDF

Follicular lymphoma grade 3: a comprehensive review.

Clin Adv Hematol Oncol 2022 Jun;20(6):384-390

King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Follicular lymphoma (FL) is a heterogeneous entity with disparate outcomes based on clinical and pathologic characteristics. An increasingly detailed understanding of high-grade FL (grade 3) has led to the identification of separate categories of FL3A and FL3B. Recently, genomic studies have made much progress in delineating the genetic differences between FL3A and FL3B. Read More

View Article and Full-Text PDF

Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells-single-center experience.

Ann Hematol 2022 Jun 22. Epub 2022 Jun 22.

BMT Unit, Tel Aviv Sourasky Medical Center, 6 Weizman St, Tel Aviv, Israel.

Anti CD-19 chimeric antigen receptor T (CAR-T) cells demonstrate effective early anti-tumor response; however, impaired hematopoietic recovery is observed in about 30% of patients with prolonged cytopenia appearing as an unmet need for optimal treatment. All adult patients given commercially available anti CD-19 CAR-T for diffuse large B cell lymphoma (DLBCL) were screened at 21-28 days after CAR-T infusion for cytopenia. In case of severe persistent cytopenia, patients were given TPO receptor agonists. Read More

View Article and Full-Text PDF

The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity.

Sci Rep 2022 Jun 21;12(1):10488. Epub 2022 Jun 21.

Institute of Biology and Medicine, College of Life and Health Sciences, Wuhan University of Science and Technology, Hubei, 430081, China.

CAR T-cell therapy is well tolerated and effective in patients with Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). However, even second- generation anti-CD30 CAR T-cells with CD28 (28z) costimulatory domains failed to achieve the desired rate of complete responses. In the present study, we developed second-generation (CD28z) and third-generation (CD28BBz) CAR T-cells targeting CD30 and investigated their efficacy in vitro and in vivo. Read More

View Article and Full-Text PDF

Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker subanalysis.

Clin Cancer Res 2022 Jun 21. Epub 2022 Jun 21.

Virgen Macarena University Hospital. Faculty of Medicine, University of Seville., Seville, Spain.

Purpose: New therapeutic options are needed in relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL). Lenalidomide based schedules can reverse rituximab refractoriness in lymphoma.

Experimental Design: In the phase II R2-GDP trial, 78 patients unsuitable for autologous stem cell transplant received treatment with R2-GDP schedule: lenalidomide 10 mg d1-14, rituximab 375 mg/m2 d1, cisplatin 60 mg/m2 d1, gemcitabine 750 mg/m2 d1 and d8 and dexamethasone 20 mg d1-3, up to 6 cycles (induction phase), followed by lenalidomide 10 mg (or last lenalidomide dose received) d1-21 every 28 days (maintenance phase). Read More

View Article and Full-Text PDF

Polatuzumab vedotin in relapsed / refractory aggressive B-cell lymphoma.

Expert Rev Anticancer Ther 2022 Jun 21. Epub 2022 Jun 21.

Division of Hematology and Medical Oncology, Department of Medicine, NYU Grossman School of Medicine, New York, NY.

Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma histology. Outcomes for patients with relapsed or refractory (R/R) disease remain suboptimal. Polatuzumab vedotin (polatuzumab) is a recently approved antibody drug conjugate that targets CD79b, with a tubulin toxin payload, that has demonstrated significant clinical activity and an acceptable toxicity profile when administered with both anti-CD20 monoclonal antibodies and chemotherapy in clinical trials. Read More

View Article and Full-Text PDF

The genomic landscape of canine diffuse large B-cell lymphoma identifies distinct subtypes with clinical and therapeutic implications.

Lab Anim (NY) 2022 Jun 20. Epub 2022 Jun 20.

Department of Veterinary Sciences, University of Turin, Grugliasco, Turin, Italy.

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid neoplasm in dogs and in humans. It is characterized by a remarkable degree of clinical heterogeneity that is not completely elucidated by molecular data. This poses a major barrier to understanding the disease and its response to therapy, or when treating dogs with DLBCL within clinical trials. Read More

View Article and Full-Text PDF

Relapsed or Refractory Diffuse Large B-Cell Lymphoma: "Dazed and Confused".

Oncology (Williston Park) 2022 Jun;36(6):366-375

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Approximately 30% to 40% of patients will develop relapsed/refractory (R/R) DLBCL, leading to significant morbidity and mortality. Salvage chemoimmunotherapy followed by high-dose chemotherapy and autologous stem cell rescue (HDT-ASCR) is the standard of care for chemosensitive and transplant-eligible R/R DLBCL. Read More

View Article and Full-Text PDF

Tibial Plasmablastic Lymphoma in a HIV-Negative Child: A Novel Extraoral Localisation.

Case Rep Hematol 2022 8;2022:4353830. Epub 2022 Jun 8.

Indus Hospital and Health Network, Plot C-76, Sector 31/5, Opposite Darussalam Society Korangi Crossing, Karachi 75190, Pakistan.

Plasmablastic lymphoma is an aggressive, high-grade non-Hodgkin lymphoma predominantly seen in HIV-infected individuals. Alongside a strong correlation with HIV, PBL can manifest in immunocompromised HIV-negative patients. A rare case of PBL in an immunocompetent and otherwise healthy child presented to Indus Hospital & Health Network (IHHN), Karachi, Pakistan. Read More

View Article and Full-Text PDF